Literature DB >> 19187176

Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee.

William D Travis1.   

Abstract

Led by the International Association for the Study of Lung Cancer (IASLC), there are currently several major international collaborative projects underway that will have a significant impact on the future reporting of lung cancer pathology. In particular, the IASLC Staging Committee has just completed an analysis of >100,000 lung cancer cases, providing the basis for proposed revisions of the current TNM staging classification. The purpose of this review is not to provide a comprehensive document on recommendations for specimen processing, but rather to discuss how the anticipated changes in the 7th edition TNM will impact on specimen processing, specifically looking at tumour size, how to deal with multiple tumours and visceral pleural invasion. TNM staging of carcinoid tumours and small cell carcinoma is also discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19187176     DOI: 10.1111/j.1365-2559.2008.03179.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  20 in total

Review 1.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 2.  Application of glycoproteomics for the discovery of biomarkers in lung cancer.

Authors:  Qing Kay Li; Edward Gabrielson; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2012-06       Impact factor: 3.494

Review 3.  Sensitivity of (18)F-FDG PET in evaluation of solitary pulmonary nodules.

Authors:  Farise Yilmaz; Gungor Tastekin
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

5.  Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.

Authors:  Qing Kay Li; Punit Shah; Yan Li; Paul O Aiyetan; Jing Chen; Rex Yung; Daniela Molena; Edward Gabrielson; Frederic Askin; Daniel W Chan; Hui Zhang
Journal:  J Proteome Res       Date:  2013-07-11       Impact factor: 4.466

Review 6.  [Novel morphological and molecular aspects of lung cancer].

Authors:  A Warth; A Stenzinger; W Weichert
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

7.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  [Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

Authors:  K Junker; R Büttner; T Langer; D Ukena
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

9.  Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Authors:  Guojin Zhang; Junlin Zhou; Yuntai Cao; Jing Zhang; Zhiyong Zhao; Wenjuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

Review 10.  Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: promise and challenge.

Authors:  Qing Kay Li; Ed Gabrielson; Frederic Askin; Daniel W Chan; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2013-01       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.